• Oligomycin A Workflows for Mitochondrial Bioenergetics

  2026-09-28

  Use Oligomycin A as a controlled mitochondrial ATP synthase inhibitor to separate ATP-linked respiration from broader metabolic stress. This practical workflow connects oxygen consumption, ATP loss, ROS, apoptosis, and sodium-driven mitochondrial failure while highlighting controls and troubleshooting decisions.

• Auranofin Workflows for Redox and Mechanobiology

  2026-09-28

  Auranofin helps researchers probe thioredoxin reductase–dependent redox control, apoptosis, and tumor radiosensitivity with quantitative concentration benchmarks. This workflow guide also shows how to pair redox experiments with mechanical-stress autophagy assays without assuming the two pathways are interchangeable.

• Berberrubine Chloride: A Redox-Centered NSCLC Framework

  2026-09-27

  Berberrubine chloride offers a useful way to investigate how thioredoxin reductase inhibition may reshape cisplatin response in non-small cell lung cancer. This article focuses on experimental interpretation: separating redox target engagement from overlapping mechanisms and designing stronger combination studies.

• Bafilomycin C1 in High-Content Cell Assays

  2026-09-26

  Use Bafilomycin C1 to test how V-ATPase-dependent organelle acidification shapes lysosomal function and autophagy readouts, with controls that help separate mechanism from general cell stress. This workflow adapts lessons from deep-learning analysis of iPSC-derived cardiomyocytes without implying that the reference study tested Bafilomycin C1.

• NRF2 Inhibition as a Translational Test

  2026-09-25

  NRF2 can support tumor-cell stress defenses yet protect vulnerable neurons from ferroptosis. This article explores how ML385 can help researchers test that context-dependent biology, validate pathway effects, and design more informative translational experiments.

• SAR405 for Resolving Autophagy Under Energy Stress

  2026-09-25

  SAR405, a selective Vps34 inhibitor, helps separate autophagy initiation from downstream membrane and lysosome effects. This article translates energy-stress research into practical assay decisions, controls, and limits for interpreting Vps34 perturbation.

• ER-Targeted Peptide Assembly and Cancer Cell Fate

  2026-09-24

  The study combines alkaline-phosphatase-instructed peptide assembly with an ER-targeting group to concentrate assemblies at the endoplasmic reticulum in cancer cells. The reported ER stress and selective cell death, alongside a greater than twofold reduction in IC50 versus non-ER-targeted intracellular EISA, suggest a way to address the concentration demands of this strategy.

• TPCA-1 for NF-κB Signaling in Septic AKI Research

  2026-09-24

  Use TPCA-1 to test whether IKK-2-dependent NF-κB activity contributes to inflammatory signaling in renal tubular cell models. This workflow connects a selective pathway perturbation to cytokine, cell-survival, and miR-202-5p/HMGB2 readouts—while keeping the septic AKI evidence distinct from TPCA-1’s established product data.

• Reactive Oxygen Species Assay Kit in Fibrosis

  2026-09-23

  Connect mitochondrial quality control to a practical live-cell superoxide readout in pulmonary-fibrosis research. This workflow uses DHE as a focused complement to mitophagy and fibrosis markers—not as a stand-alone measure of every reactive oxygen species.

• AG-120 (Ivosidenib) Workflows for IDH1 AML

  2026-09-23

  Build a mechanism-first workflow around AG-120 (Ivosidenib) to connect 2-hydroxyglutarate reduction with erythropoietin-induced differentiation in IDH1-mutant AML models. The approach combines metabolite, phenotype, and CD44-linked metabolic readouts for stronger interpretation than viability testing alone.

• Estradiol and the Estrogen Receptor–Autophagy Axis

  2026-09-22

  Estradiol is more than a hormonal stimulus: it is a mechanistic probe for connecting estrogen receptor biology with autophagy, fibrosis, and multi-organ resilience. This article translates recent human-cohort and mouse evidence into a practical framework for designing receptor-resolved, translational studies with 17 beta-estradiol.

• Wnt-C59 PORCN Inhibitor Workflow Guide

  2026-09-22

  Wnt-C59 enables secretion-focused interrogation of Wnt biology, from Wnt3A reporter assays to cholangiocarcinoma models. This guide also shows how to use a PORCN inhibitor as a mechanistic control when studying lithium-engineered exosomal Wnt10a and osteogenesis.

• Auranofin at the Redox–Metabolism Interface

  2026-09-21

  Auranofin offers translational researchers a way to interrogate thioredoxin reductase, oxidative stress, apoptosis, and radiosensitization within increasingly metabolism-focused cancer models. This article connects established product evidence with the FOXO3/YAP metabolic framework in hepatocellular carcinoma while defining the experiments needed to distinguish mechanistic promise from therapeutic proof.

• ABT-263 (Navitoclax): Translational Apoptosis Strategy

  2026-09-21

  ABT-263 (Navitoclax) is more than a Bcl-2 family inhibitor: it is a mechanistic probe for determining how mitochondrial apoptotic priming, anti-apoptotic protein dependence, and treatment resistance interact. This thought-leadership guide translates BH3-mimetic biology into practical strategies for cancer models, apoptosis assays, and translational study design.

• Verapamil HCl: Calcium Signaling Workflows

  2026-09-20

  Learn how to use Verapamil HCl as both an L-type calcium channel blocker and a mechanistic probe in myeloma, apoptosis, transporter, and arthritis inflammation studies. The workflow emphasizes formulation control, orthogonal readouts, and safeguards against confusing calcium-channel effects with altered intracellular drug accumulation.

555 records 3/37 page Previous Next 12345 下5页 Last page